不同中心内镜判读模型对克罗恩病治疗结局的影响:BERGAMOT试验探索性队列数据
该研究基于BERGAMOT随机对照试验探索性诱导队列,比较5种内镜判读模型对克罗恩病治疗结局评估的影响。
要点
- 包含2名判读者的模型较单判读者模型显示更低的安慰剂率。
- 联合本地与中心判读者的模型在内镜改善上效应量最大(Δ=16.2%)。
- 在etrolizumab组,2名判读者模型对SES-CD的变异性最低。
核心结论
- 克罗恩病中心内镜判读模型影响安慰剂应答率和效应量,纳入本地判读者可能重要。
研究设计与样本
- BERGAMOT试验(NCT02394028)探索性诱导队列的事后亚组分析,患者随机分配至etrolizumab或安慰剂。
- 基线和第14周内镜由本地判读者和2名中心判读者独立评分SES-CD,比较5种判读模型。
主要发现
- 包含2名判读者的模型安慰剂率为3.4%,低于单本地判读者(11.9%)和单中心判读者(6.8%)。
- 基于内镜改善(SES-CD较基线下降≥50%)的效应量在联合本地判读者与1或2名中心判读者的模型中最高(Δ=16.2%)。
- 在etrolizumab组,2名判读者模型对SES-CD的变异性最低。
临床怎么用
- 在克罗恩病临床试验中,采用包含本地判读者与中心判读者的联合判读模型可能降低安慰剂率并提高效应量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Endoscopic assessment of mucosal appearance by independent central reading has become the standard method to assess Crohn's disease activity in clinical trials. The performance characteristics of various endoscopy reading models have yet to be systematically evaluated. METHODS: This substudy included patients with Crohn's disease in the exploratory induction cohort of the BERGAMOT trial (NCT02394028) randomly assigned to etrolizumab or placebo. Endoscopies conducted at baseline and week 14 were independently scored using the Simple Endoscopic Score for Crohn's Disease (SES-CD) by a local reader (LR) and 2 central readers (CRs). Five endoscopy reading models were compared: single LR, single CR, average of 2 CRs, and 2 models incorporating the LR and 1 or 2 CRs depending on alignment between the LR and the CR, defined according to a sliding scale applied to a range of scores. RESULTS: Five hundred thirty-five videos were scored. Models involving 2 readers demonstrated lower placebo rates (3.4%) than the single LR (11.9%) and the single CR (6.8%) models. Treatment effect size based on endoscopic improvement (≥50% reduction in SES-CD from baseline) was highest with the 2 models incorporating the LR and 1 or 2 CRs (Δ = 16.2%). Further, in the etrolizumab arm, models with 2 readers demonstrated the lowest variability for the SES-CD. CONCLUSIONS: Central endoscopy reading models in Crohn's disease have an impact on placebo response rates and effect size. Incorporating the LR appears to be important because models using both CRs and LRs resulted in the greatest treatment effect size for endoscopic improvement with etrolizumab, lower placebo rates, and reduced variability.
引用
- Reinisch W, Mishkin DS, Oh YS, et al. Impact of various central endoscopy reading models on treatment outcome in Crohn's disease using data from the randomized, controlled, exploratory cohort arm of the BERGAMOT trial. Gastrointest Endosc. 2020. PMID: 32464142. doi:10.1016/j.gie.2020.05.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。